- About the Center
- Research Programs
- Addiction Genetics and Pharmacogenetics Division
- Addiction Treatment and Medication Development Division
- Brain-Behavioral Vulnerabilities Laboratory
- HIV/AIDS Prevention Research Division
- Clinical Trials Network
- Novel Interventions in Criminal Justice Populations Division
- Continuing Care and Assessment Division
- Integrated Care for Primary Care
- Clinical Trial Participation
- Treatment Options
- Affiliated Divisions
- Center Faculty
- Post Doctoral Fellowships
- Public Education and Policy Work
- Contact Us
- Support Our Work
Addiction Genetics and Pharmacogenetics Division
The Division of Addiction Genetics and Pharmacogenetics focuses on the role of genetic variation and epigenetics as factors both in the risk of addiction and as moderators of response to both psychosocial and pharmacological interventions. The Division supports research on subgroups of addicted individuals that are genetically homogeneous with respect either to the development of an addictive disorder or its response to treatment. Treatment trials supported by the Division employ state-of-the art clinical trial designs (e.g., adaptive trial designs) and genetic and epigenetic methods (including candidate gene and genomewide approaches).
A major focus of the division is on gene finding for all major substance use disorders, including alcohol, cocaine, opioids, and cannabis, and psychiatric disorders that co-occur with addiction. A second major focus of the division is on the identificatoin of pharmacogenetic moderators of medications to treat alcohol use disorder.
Amy Hart, PhD
Dr. Hart is a postdoctoral fellow working under the mentorship of Dr. Henry Kranzler. She received her Ph.D. in Human Genetics from the University of Chicago in 2013, where she studied the genetic influences on the acute response to d-amphetamine, a proposed intermediate phenotype for amphetamine abuse. Her current work focuses on elucidating the genetic influences on the risk for alcoholism and other substance dependencies, with a particular interest in the analysis of large, genome-wide datasets.
Kranzler, H.R., Armeli, S., Feinn, R., Tennen, H., Gelernter, J., & Covault, J. GRIK1 genotype moderates topiramate’s effects on daily drinking level, expectations of alcohol’s positive effects, and desire to drink. International Journal of Neuropsychopharmacology, 2014 April 30:1-8. [Epub ahead of print].
Kranzler, H.R., Covault, J., Feinn, R., Armeli, S., Tennen, H., Arias, A.J., Gelernter, J., Pond, T., Oncken, C., & Kampman, K.M. Topiramate treatment of heavy drinkers: moderation by a GRIK1 polymorphism. American Journal of Psychiatry, 171(4):445-452, 2014.
Bi, J., Gelernter, J., Sun, J., & Kranzler, H.R. Comparing the utility of homogeneous subtypes of cocaine use and related behaviors with DSM-IV cocaine dependence as traits for genetic association analysis. American Journal of Medical Genetics, 165B(2): 148-56, 2014.
Gelernter, J., Kranzler, H.R., Sherva, R., Almasy, L., Koesterer, R., Anton, R., Preuss, U.W., Ridinger, M., Rujescu, D., Wodarz, N., Zill, P., Zhao, H., & Farrer, L.A. Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci. Molecular Psychiatry, 19(1):41-49, 2014.
Gelernter, J., Kranzler, H.R., Sherva, R., Koesterer, R., Almasy, L., Zhao, H., & Farrer, L.A. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biological Psychiatry, 76(1):66-74, 2014.
Gelernter, J., Sherva, R., Koesterer, R., Almasy, L., Zhao, H., Kranzler, H.R., & Farrer, L. Genome-wide association study of cocaine dependence and related traits: FAM53B identified as a risk gene. Molecular Psychiatry, 19(6):717-723, 2014.
Back to Top